Table 1. Characteristics of the participants with Parkinson’s disease (PD) in the T-PEMF intervention group and the PD-control group.
| T-PEMF, N = 14 | PD-Control, N = 8 | P-values | |
|---|---|---|---|
| Sex (female/male) | 5/9 | 2/6 | 0.604a |
| Age (years) | 66.6 (7.6) | 70.5 (6.3) | 0.240b |
| Height (cm) | 172 (8.7) | 172 (6.6) | 0.925b |
| Weight (kg) | 73.5 (11.4) | 73.3 (10.5) | 0.960b |
| UPDRS-total | 46.4 (22.2) | 35.3 (5.1) | 0.099c |
| UPDRS-motor | 27.8 (15.0) | 21.1 (3.4) | 0.137c |
| UPDRS-bradykinesia | 14.6 (8.1) | 12.3 (3.2) | 0.351c |
| Hoehn-Yahr score | 2.0 (2.0–2.9) | 2.3 (2.0–2.5) | 0.904 d |
| MMSE | 29.5 (28.0–30.0) | 30.0 (28.8–30.0) | 0.527d |
| Levodopa equivalent dose (mg/day) | 498.3 (259.1) | 469.4 (148.6) | 0.777b |
| Disease duration (years) | 6.2 (3.5) | 5.3 (3.7) | 0.581b |
a Chi-square test
b T-test, equal variance
c T-test, unequal variance (Cochran-Cox)
d Mann-Whitney U-test
Unified Parkinson’s disease Rating Scale total score (UPDRS-total, range 0–199), motor score (UPDRS-motor, range 0–108) and bradykinesia score (UPDRS-bradykinesia, range 0–36). Mini-Mental State Examination (MMSE, range 0–30).
Disease duration is the time period from diagnosis to study inclusion. Data are means (SD), except for MMSE and Hoehn-Yahr where medians and inter-quartile ranges are reported.